74 related articles for article (PubMed ID: 10369603)
1. Ocular inflammation associated with alendronate therapy.
Mbekeani JN; Slamovits TL; Schwartz BH; Sauer HL
Arch Ophthalmol; 1999 Jun; 117(6):837-8. PubMed ID: 10369603
[No Abstract] [Full Text] [Related]
2. Nodular scleritis following alendronate therapy.
Tabbara KF
Ocul Immunol Inflamm; 2008; 16(3):99-101. PubMed ID: 18569796
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-associated scleritis: a case report and review.
Leung S; Ashar BH; Miller RG
South Med J; 2005 Jul; 98(7):733-5. PubMed ID: 16108245
[TBL] [Abstract][Full Text] [Related]
4. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
French DD; Margo CE
Retina; 2008 Jun; 28(6):889-93. PubMed ID: 18536608
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
Fraunfelder FW; Winthrop K; Suhler E; Choi D; Fraunfelder FT
Retina; 2009 Feb; 29(2):285-6; author reply 286-7. PubMed ID: 19202428
[No Abstract] [Full Text] [Related]
6. Nongranulomatous anterior uveitis associated with alendronate therapy.
Salmen S; Berrueta L; Sánchez N; Montes H; Borges L
Invest Clin; 2002 Mar; 43(1):49-52. PubMed ID: 11921747
[TBL] [Abstract][Full Text] [Related]
7. [Alendronate].
Lindberg M
Ugeskr Laeger; 1998 Oct; 160(44):6367-8. PubMed ID: 9810249
[No Abstract] [Full Text] [Related]
8. Alendronate-induced lichen planus.
Lazarov A; Moss K; Plosk N; Cordoba M; Baitelman L
Isr Med Assoc J; 2002 May; 4(5):389-90. PubMed ID: 12040836
[No Abstract] [Full Text] [Related]
9. Improper alendronate administration and a case of pill esophagitis.
Rimmer DE; Rawls DE
Am J Gastroenterol; 1996 Dec; 91(12):2648-9. PubMed ID: 8947013
[No Abstract] [Full Text] [Related]
10. [Does alendronate reduce the risk of fractures in postmenopausal women with osteoporosis?].
Häuselmann HJ
Praxis (Bern 1994); 1997 Apr; 86(15):613. PubMed ID: 9213912
[No Abstract] [Full Text] [Related]
11. Alendronate: a bisphosphonate for treatment of osteoporosis.
Kirk JK; Spangler JG
Am Fam Physician; 1996 Nov; 54(6):2053-60. PubMed ID: 8900364
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous bilateral atypical femoral fractures after alendronate therapy.
Zafeiris CP; Stathopoulos IP; Kourkoumelis G; Gkikas E; Lyritis GP
J Musculoskelet Neuronal Interact; 2012 Dec; 12(4):262-4. PubMed ID: 23196269
[No Abstract] [Full Text] [Related]
13. [Can tumor necrosis factor inhibitors induce sclero-uveitis?].
Le Garrec J; Marcelli C; Mouriaux F
J Fr Ophtalmol; 2009 Sep; 32(7):511.e1-6. PubMed ID: 19535169
[TBL] [Abstract][Full Text] [Related]
14. The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.
Mersereau JE; Khouri C; Jaffe RB
Fertil Steril; 2010 Aug; 94(3):1138-40. PubMed ID: 20056199
[TBL] [Abstract][Full Text] [Related]
15. Topical cyclosporine A as a steroid-sparing agent in steroid-dependent idiopathic ocular myositis with scleritis: a case report and review of the literature.
Gumus K; Mirza GE; Cavanagh HD; Karakucuk S
Eye Contact Lens; 2009 Sep; 35(5):275-8. PubMed ID: 19687744
[TBL] [Abstract][Full Text] [Related]
16. [Esophagitis associated with use of alendronate in 5 postmenopausic patients].
Luciani J; Pigatto V; Naves A; Fay M; Silvestre Begnis M; Piola JC; Prada DB; Pedrana R
Acta Gastroenterol Latinoam; 2001 May; 31(2):59-63. PubMed ID: 11471319
[TBL] [Abstract][Full Text] [Related]
17. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
Bize R; Lamy O; Peytremann-Bridevaux I
Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
[No Abstract] [Full Text] [Related]
18. An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis.
Terashima T; Hiramatsu K; Shimatani A; Matsuda M; Ogino H; Satomura Y; Noda Y
Endoscopy; 2006; 38 Suppl 2():E37. PubMed ID: 17366400
[No Abstract] [Full Text] [Related]
19. The comparative gastrointestinal tolerability of proprietary versus generic alendronate in patients treated for primary osteoporosis.
Landfeldt E; Ström O
Bone; 2012 Oct; 51(4):637-42. PubMed ID: 22842329
[TBL] [Abstract][Full Text] [Related]
20. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
